

News Release

Lonza Announces Executive Committee Changes

- **Marc Funk has been appointed COO of the Pharma&Biotech segment as Stephan Kutzer has decided to leave Lonza.**

Basel, Switzerland, 28 April 2014 – Lonza Group Ltd announced today changes in the composition of Lonza's Executive Committee (EC) to ensure continuity and focused delivery of the Pharma&Biotech growth strategy.

As of 1 July 2014, Marc Funk will take on the full leadership role for the Pharma&Biotech segment. Stephan Kutzer has announced that he will be leaving Lonza, but he will ensure that the handover is completed by that date. For a period of time, he will continue to complete additional transitional activities as required.

"Marc has been the Group's Chief Legal Officer and Board Secretary since 2009 and a member of the EC since 2012," said Richard Ridinger, CEO of Lonza. "He has already successfully managed operational and commercial projects in the Pharma&Biotech network and has been responsible for Global Quality in Pharma&Biotech for more than a year. Also he has broad experience in this field as he was formerly co-founder of a biotech research company and has had a strong commercial focus in other parts of his career. I am confident he'll be able to steer that segment through this critical growth phase and into the future."

During the transition period, Marc Funk will continue as the Group's Chief Legal Officer and Board Secretary until his successor for this role is announced in due course.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 10,000 employees worldwide. The company generated sales of about CHF 3.6 billion in 2013 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Lonza's stock is publicly traded on the Swiss and the Singapore stock exchanges. Further information can be found at www.lonza.com.

Corporate

News Release

Lonza

Lonza Group Ltd
Muenchensteinerstrasse 38
4002 Basel, Switzerland
www.lonza.com

Lonza Contact Information

Lonza Group Ltd
Head Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

Lonza Group Ltd
Head Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
Fax +41 61 316 9840
constance.ward@lonza.com